特瑞普利单抗致暴发性1型糖尿病一例  

Fulminant type 1 diabetes induced by toripalimab:a case report

作　　者：王亚宁 张磊[3] 赵鹏[3] 姚民秀[2] 徐倩[2] 张方华[2] WANG Ya-ning;ZHANG Lei;ZHAO Peng;YAO Min-xiu;XU Qian;ZHANG Fang-hua(School of Clinical Medicine,Weifang Medical University,Shandong Weifang 261053,China;Department of Endocrinology,Qingdao Central Hospital Affiliated to Qingdao University,Shandong Qingdao 266042,China;Department of Clinical Laboratory,Qingdao Central Hospital Affiliated to Qingdao University,Shandong Qingdao 266042,China)

机构地区：[1]潍坊医学院临床医学院,山东潍坊261053 [2]青岛大学附属青岛市中心医院内分泌科,山东青岛266042 [3]青岛大学附属青岛市中心医院检验科,山东青岛266042

出　　处：《临床药物治疗杂志》2023年第7期84-86,共3页Clinical Medication Journal

摘　　要：免疫检查点抑制剂引起的暴发性1型糖尿病虽然发生率极低,但其可导致循环衰竭和致命性心律失常,死亡率高,是一种潜在的致命性疾病,临床需高度警惕。本文报道1例应用特瑞普利单抗治疗12周后出现暴发性1型糖尿病的病例,通过及时治疗病情好转,出院后一直给予胰岛素维持治疗。The incidence rate of fulminant type 1 diabetes caused by immune checkpoint inhibitors is low,it is a potentially fatal disease that needs to be highly vigilant because it can lead to circulatory failure and fatal arrhythmia with high mortality.In this paper we report a case of fulminant type 1 diabetes after 12 weeks of treatment with toripalimab.Through timely treatment,the patient's condition improved and insulin maintenance treatment was continuously administered after discharge.

关 键 词：特瑞普利单抗 暴发性1型糖尿病 程序性细胞死亡受体1 胰岛素 

分 类 号：R979.5[医药卫生—药品] R587.1[医药卫生—药学]